hungrier on semaglutide Still hungry… even after a full meal? works by enhancing GLP-1 activity, a hormone involved in appetite regulation and fullness signaling. It helps slow gastric emptying and supports stronger satiety cues Still hungry on semaglutide? 9

Explore BPS Biosciences solutions for GLP-1R research in diabetes

We summarize the effects of semaglutide, dosages utilized, potential negative outcomes, and users' before-and-after results.

Wondering about Ozempic and other weight loss medications, such as GLP-1s

Semaglutide has transformed weight management for millions, but questions about safety and long-term use persist

Read or listen now!

Each has demonstrated the potential to emerge as either a Best-in-Class or First-in-Class treatment in the obesity field.The ADA 2025 presentations will cover: Phase 1 Trial Results for HM15275, Robust anti-obesity effect and mechanistic insights of HM15275 in animal models of obesity, Mechanistic insights into HM15275s improved quality of weight loss compared to tirzepatide (Zepbound), Weight loss and differentiated body composition improvement effects of HM17321, Glycemic control improvement observed with HM17321, and Synergistic effects on body composition improvement when combining HM15275 and HM17321A large delegation from Hanmis R&D Center will attend ADA 2025 to present poster sessions showcasing the companys novel therapeutic approaches in obesity treatment and to explore potential collaborations with leading global pharmaceutical companies. HM15275: Next-Generation Triple Agonist Targeting Quantity and Quality of Weight LossHM15275 is engineered to optimize the activity balance of GLP-1, GIP, and glucagon (GCG) receptors, delivering targeted obesity treatment while also addressing comorbid metabolic conditions such as diabetes, cardiovascular, and renal disease